Detalhe da pesquisa
1.
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
N Engl J Med
; 378(4): 354-369, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29365309
2.
Glecaprevir/pibrentasvir for 8â¯weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
J Hepatol
; 72(3): 441-449, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682879
3.
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
J Viral Hepat
; 26(8): 1027-1030, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30980576
4.
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
J Viral Hepat
; 26(3): 337-349, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30421537
5.
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Hepatology
; 68(4): 1298-1307, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672891
6.
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
Clin Infect Dis
; 67(7): 1010-1017, 2018 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29566246
7.
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
J Infect Dis
; 215(4): 599-605, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28329334
8.
Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
Antimicrob Agents Chemother
; 61(2)2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27919899
9.
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
N Engl J Med
; 370(21): 1973-82, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24725237
10.
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Clin Infect Dis
; 62(8): 972-9, 2016 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26740513
11.
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
J Hepatol
; 64(2): 301-307, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26476290
12.
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Antimicrob Agents Chemother
; 60(10): 6244-51, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27503645
13.
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Antimicrob Agents Chemother
; 60(5): 2965-71, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26953200
14.
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Liver Int
; 35(11): 2358-62, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26248955
15.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
JAMA
; 313(12): 1223-31, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25706092
16.
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Antimicrob Agents Chemother
; 54(11): 4903-6, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20805393
17.
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
PLoS One
; 14(1): e0208506, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30601818
18.
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Adv Ther
; 36(12): 3458-3470, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31646465
19.
A Phase 1 Study to Evaluate the Effect of Crushing, Cutting Into Half, or Grinding of Glecaprevir/Pibrentasvir Tablets on Exposures in Healthy Subjects.
J Pharm Sci
; 107(6): 1724-1730, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29476763
20.
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
Open Forum Infect Dis
; 4(3): ofx154, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948180